戻る Agenda
Understanding of Different Set Ups of PPP, Benefits of PPPs and Learnings of Recent Projects to Facilitates Future Success of Such Collaborations
Session Chair(s)
Katrin Rupalla, PharmD, MBA
Senior Vice President
H. Lundbeck A/S, Denmark
Public-Private-Partnerships (PPP) are intended to facilitate collaboration amongst multiple stakeholders in research to advance the development of medicines to address important public health needs. These collaborations often focus on areas with a low innovation rate and of high unmet medical need. This session will discuss some important learnings from ongoing and recently concluded PPP projects and how these should be considered for other projects.
Learning Objective : Understanding of different set ups of PPP, benefits of PPPs and learnings of recent projects to facilitates future success. of such collaborations
Speaker(s)
What are Important Considerations from an Industry Perspective When Participating in a PPP Project
Christian Brasen, PhD, MSc
Lundbeck A/S, Denmark
Project Manager, Biometrics
How to Ensure Regulatory Acceptability of PPP Outcomes
Nathalie Seigneuret, PharmD
Innovative Medicines Initiative (IMI), Belgium
Senior Scientific Project Manager
Considerations for Participation in PPP Projects: Learnings from the CRITICAL PATH Parkinson’s Consortium
Diane Stephenson, PhD
Critical Path Institute, United States
Executive Director